Replies to post #202074 on Biotech Values

[north40000]

In a "mono-therapy"? I did not listen to BMY call/webcast.

" BMY's clear intention on its ASCO webcast was to convey that they're including a broader group of first-line NSCLC patients than a 50% cut-off based on MRK's assay."

[DewDiligence]

More on the same topic—Opdivo-vs-Keytruda in first-line NSCLC:

http://www.bloomberg.com/gadfly/articles/2016-06-17/merck-keytruda-lung-cancer-edge-on-opdivo-won-t-last